Evidence map›Paper›PMID 30023905›Full record

ArticleACS omega2018

Optimization of Formulations Consisting of Layered Double Hydroxide Nanoparticles and Small Interfering RNA for Efficient Knockdown of the Target Gene.

Yanheng Wu, Wenyi Gu, Chen Chen, Son Trong Do, Zhi Ping Xu

Abstract read
In one paragraph

Article in ACS omega, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Lipid nanoparticle delivery of siRNA targetingZhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2023
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yanheng WuAustralian Institute for Bioengineering and Nanotechnology and School of Biomedical Sciences, The University of Queensland, St Lucia, Queensland 4072, Australia.
Wenyi GuAustralian Institute for Bioengineering and Nanotechnology and School of Biomedical Sciences, The University of Queensland, St Lucia, Queensland 4072, Australia.
Chen ChenAustralian Institute for Bioengineering and Nanotechnology and School of Biomedical Sciences, The University of Queensland, St Lucia, Queensland 4072, Australia.
Son Trong DoThe Princess Alexandra Hospital, 199 Ipswich Rd, Woolloongabba, Queensland 4102, Australia.
Zhi Ping XuAustralian Institute for Bioengineering and Nanotechnology and School of Biomedical Sciences, The University of Queensland, St Lucia, Queensland 4072, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Layered double hydroxide (LDH) nanoparticles (NPs) are safe and effective vectors for small interfering RNA (siRNA) delivery. However, it is unclear whether there are optimal parameters for the efficient delivery of functional siRNA using LDH NPs. In this research, we comprehensively examined the effect of parameters, such as the mixing method and LDH/siRNA mass ratio on siRNA silencing capability. We first noted that the best way for loading gene segments (25 bp dsDNA and siRNA) is to add gene molecules to 100 nm LDH and then diluting in Dulbecco's modified Eagle's medium. Very interestingly, the optimal LDH/gene mass ratio is around 20:1 in terms of cellular uptake amount of gene segments, whereas this ratio is shifted to around 5:1 in terms of target gene silencing efficacy, which has been reasonably explained. The optimization for LDH NP-based gene delivery system may provide the guidance for more efficient in vitro and in vivo siRNA delivery using the optimal parameters.

Identifiers

PMID30023905
PMCPMC6045353

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.